1 Burden, Causation, and Particularities of long-COVID in African populations: A

- 2 rapid systematic review
- 3
- 4 Authors: Peter S. Nyasulu^{1,2**}, Jacques L. Tamuzi¹, Rajiv T. Erasmus³
- 5

6 Affiliations

- ⁷ ¹Department of Global Health, Faculty of Medicine and Health Sciences,
- 8 Stellenbosch University, Cape Town, South Africa
- ⁹ ²School of Public Health, Faculty of Health Sciences, University of the
- 10 Witwatersrand, Parktown, Johannesburg, South Africa.
- ¹¹ ³Division of Chemical Pathology, Department of Pathology, Faculty of Medicine and
- 12 Health Sciences, Stellenbosch University & NHLS Tygerberg Hospital, Cape Town,
- 13 South Africa
- 14
- 15 ****Corresponding author**: Professor Peter Nyasulu. Division of Epidemiology and
- 16 Biostatistics, Department of Global Health, Faculty of Medicine and Health Sciences,
- 17 Stellenbosch University, Cape Town, South Africa. pnyasulu@sun.ac.za
- 18
- 19
- 20
- 21
- 22
- 23
- 24

25 Abstract

Background: The global estimated prevalence of long COVID-19 is 43%, and the most common symptoms found globally are fatigue, confusion, or lack of confusion, and dyspnea, with prevalence rates of 23%, 14%, and 13%, respectively. However, long COVID still lacks an overall review in African populations. The aim of this review was to determine the prevalence of long COVID, its most common symptoms, comorbidities, and pathophysiological mechanisms.

Methods: A systematic review of long COVID in African populations was conducted.
The random effects model was used to calculate the pooled prevalence rates (95%
CI). If the results could not be pooled, a narrative synthesis was performed.

Results: We included 14 studies from 7 African countries, totaling 6,030 previously 35 SARS-CoV-2 infected participants and 2,954 long COVID patients. Long COVID had 36 37 a pooled prevalence of 41% [26%-56%]. Fatigue, dyspnea, and confusion or lack of 38 concentration were the most common symptoms, with prevalence rates (95% CI) of 39 41% [26%-56%], 25% [12%-38%], and 40% [12%-68%], respectively. Long COVID was associated with advanced age, being female, more than three long COVID 40 symptoms in the acute phase, initial fatigue and dyspnea, post-recovery stress, 41 42 sadness, and sleep disturbances, and loss of appetite at symptoms onset, mild, moderate, and severe, pre-existing obesity, hypertension, diabetes mellitus, and the 43 presence of any chronic illness (P ≤ 0.05). According to our review, high micro clot 44 45 and platelet poor plasma (PPP) viscosity explain the pathophysiology of long COVID. **Conclusion:** Long COVID prevalence in Africa was comparable to the global 46 prevalence. However, the prevalence of the most common symptoms was higher in 47 48 Africa. Comorbidities associated with long COVID may lead to additional 49 complications in African populations due to hypercoagulation and thrombosis.

- 51 African populations

- ...

75 **1. Background**

Post-Acute Sequelae of severe acute respiratory coronavirus 2 (SARS-CoV-2) 76 77 (PASC), colloquially referred to as "long coronavirus disease (COVID)", is a poorly 78 understood condition characterized by prolonged COVID-19 symptoms and/or the development of new symptoms following the resolution of acute SARS-CoV-2 79 80 infection. While there is still no formal clinical definition of long COVID, findings 81 reported in individuals experiencing long COVID include general symptoms 82 (tiredness or fatigue that interferes with daily life, symptoms that get worse after 83 physical or mental effort (also known as "post-exertional malaise"), fever, respiratory 84 and heart symptoms (difficulty in breathing or shortness of breath, cough, chest pain, 85 fast-beating or heart palpitations, neurological symptoms (difficulty thinking or concentrating, headache, insomnia, dizziness, pins-and-needles feelings, change in 86 87 smell or taste, depression or anxiety), digestive symptoms (Gastroesophageal reflux (GERD), diarrhoea, and stomach pain) 88 disease and other symptoms (hyperlipidaemia, thromboembolism, kidney disorders, joint or muscle pain, rash and 89 changes in menstrual cycles).¹⁻⁴ For example, National Institute for Health and Care 90 Excellence (NICE) defined the "Long COVID" as "signs and symptoms that develop 91 92 during/after the COVID-19 infection persisting for more than 4 weeks and could not 93 be explained by any other diagnosis". In this categorization, the long COVID consists 94 of two categories, "ongoing symptomatic COVID-19", which indicates the symptoms last for 4-12 weeks; and "post-COVID-19 syndrome", which means symptom 95 persistence beyond 12 weeks.^{5,6} Baig et al. suggested using the term "Chronic 96 COVID syndrome (CCS)" as opposed to "Long-COVID" or "Long Haulers".⁷ He also 97 presented an organ-based staging of the illness to prioritize immediate care needs.^{5,7} 98

As of 21 December 2022, Africa recorded approximately 9.4 million confirmed 99 100 COVID-19 cases accounting for just 1.45 % of 649,2 million global COVID-19 confirmed cases⁸, despite containing 12.5% of the global population. ^{9,10} In Africa, 101 102 the picture of long COVID is not well described as little research has been conducted 103 in this emerging field. However, few studies have been conducted on the burden of 104 long COVID in Africa, long COVID prevalence has been reported to vary across and 105 within African countries. Dryden et al. reported the highest long COVID prevalence compared to other studies conducted worldwide.¹¹ However, a single study cannot 106 107 reflect the prevalence of the African continent. While Peluso et al. concluded that HIV status strongly predicted the presence of long COVID.¹² Other studies found 108 109 that diabetes, cardiovascular disease, and female sex were all linked to long COVID. ^{13,14} Given the high prevalence of these comorbidities on the African continent, an 110 111 overall study focusing on African populations is required. We determined the burden 112 of long COVID, prevalent symptoms, key findings, risk factors, and plausible 113 pathophysiology in African populations in this review.

114 **2. Methods**

115 This section covers study selection strategy, study design, eligibility, inclusive and 116 exclusive criteria, and quality of assessment and synthesis.

117 **2.1. Study selection strategy**

To ensure the reproducibility and transparency of our findings, studies were selected for systematic reviews (from January 2020 to December 2022) in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.¹⁵ The studies were chosen based on the following key review research questions: How prevalent is long COVID in African populations? What are the most 123 prevalent long COVID symptoms in African populations? What factors and 124 comorbidities are associated with long COVID in African populations? To respond 125 these questions, we searched PubMed, Medline, Google Scholar, the WHO COVID-126 19 Research Database, medRxiv, and bioRxiv for potential studies on long COVID-127 19 in African populations, employing the following MESH terms and key words as the search strategy: "Post-Acute COVID-19 Syndromes" OR "Long Haul COVID-19" OR 128 129 "Long COVID" OR "Post-Acute Sequelae of SARS-CoV-2 Infection" OR "Post-130 COVID Conditions" OR "Post-COVID Condition" OR "Long-Haul COVID" AND 131 "Comorbidities" AND "epidemiology" [Subheading] OR "Burden of Disease" AND 132 "African populations" OR "African people" OR "Africans". Only English-language 133 studies were considered. To remove duplicates, studies were imported into the 134 Endnote online tool. The authors took a step-by-step approach, beginning with 135 systematic reviews. The remaining abstracts were screened by one reviewer, and all 136 excluded abstracts were screened by another. One reviewer screened all full-text 137 papers, and a second screened those that were not. When necessary, a third 138 reviewer was brought in. One reviewer (JLT) extracted the data, and another (PSN) 139 double-checked it. The study ID, setting, population, long COVID prevalence, 140 comorbidities, and statistically significant findings were all included in the data. The 141 Newcastle-Ottawa Scale (NOS) risk of bias assessment was used to evaluate the study's quality.¹⁶ 142

143

144 **2.2. Study design eligible inclusion and exclusion criteria**

We only included studies that looked at long COVID prevalence, symptoms, associated comorbidities, and other important findings in African populations. This review included people of all ages. We also included African studies on COVID

symptoms that persisted. Furthermore, studies on asymptomatic COVID-19 and
 those assessing COVID recovery time were excluded from this review.

150 **2.3. Data extraction and synthesis**

151 We created a data extraction table to collect information related to the research 152 questions. However, data were extracted for the four most common long COVID symptoms. Data extraction was completed by one reviewer (JLT) and independently 153 checked by a second reviewer (PSN), with discrepancies resolved through 154 155 discussion. Only evidence directly relevant to the review question was extracted. The 156 data included in the meta-analysis, primarily long COVID prevalence and the four 157 most common symptoms, were extracted into an Excel spreadsheet and the effect 158 sizes (ES) and standard errors were calculated. Long COVID prevalence was 159 calculated for each included study by dividing the total number of SARS-CoV-2 160 infected patients by the total number of long COVID. The number of COVID-19 161 patients with symptoms divided by the total number of long COVID patients yielded 162 the prevalence for each long COVID symptom.

A meta-analysis was performed for long COVID prevalence and the four most 163 common symptoms. According to the Cochrane handbook¹⁷, the prevalence rates 164 165 were pooled using the random effects model because we expected significant heterogeneity (1²>50%). Subgroup analyses based on setting and long COVID were 166 167 performed a priori. For small sample studies, Egger's regression and Begg's tests 168 were used to assess publication bias. The P-value for statistical significance was set 169 at 0.05 for all analyses. Stata (V.16, Stata Corp, College Station, Texas, USA) was 170 used for the meta-analysis. Comorbidities and key findings were summarized in a 171 narrative format.

173

174

175 **3. Results**

The databases yielded 453 articles, 39 duplicates were removed, and 414 titles and abstracts were screened for eligibility. 387 records were excluded because they were unsuitable for the review. Full texts were obtained for the 27 studies, but 13 were excluded because two were protocols, nine were reports, and two were letters to the editors. Then, 14 studies were included in our analysis, with 9 included in the meta-analysis and 5 included in the narrative synthesis. The review flow chart is shown in Figure 1.



In

cl

ud

ed

- 213
- 214 215

216 **3.1. Study and participant characteristics**

217 Fourteen studies were included in this review. Among them, five were case control studies conducted in South Africa and Morocco¹⁸⁻²², three retrospective cohort 218 studies undertaken in Nigeria and South Africa²³⁻²⁵, two prospective cohort studies 219 (South Africa and Zambia)^{11,26}, two retrospective cross-sectional studies done in 220 South Africa and Egypt^{27,28} and two cross-Sectional studies undertaken Ghana and 221 Egypt^{29,30}. This review included a total of 6, 030 previously SARS-CoV-2 infected 222 223 participants and 2,954 long COVID patients. Seven studies reported that long COVID was prevalent among females. 11,18,20,25-29 In contrast, three studies high 224 prevalence rates among males.^{23,24,30} Long COVID range of age was 1 to 85 225 years.^{11,18,19,22-24,27,28,30} Methodological quality of the included studies was reported in 226 Supplementary file 1. 227

3.2. Meta-analysis

The pooled results of long COVID prevalence (95% CI) in African populations 229 230 revealed a 41% [26%-56%] overall prevalence (Figure 2). This prevalence, however, 231 varied significantly across studies conducted in different African countries. Egypt had 232 the highest prevalence, at 59% [55%-64%] (Figure 2). Nigeria had a prevalence rate 233 of 49% [31%-66%]. (Figure 2). South Africa, Morocco, and Zambia had prevalence rates of 47% [7%-86%], 47% [38%-56%], and 15% [10%-20%], respectively (Figure 234 235 2). Ghana had the lowest prevalence of 2% [2%-3%] (Figure 2). The degree of heterogeneity between studies was high, with $I^2 = 99.5\%$. 236

9

Figure 1: Flow chart of studies reviewing long COVID in African populations

237 The prevalence of the most common long COVID symptoms in African populations 238 was assessed in Figure 3. According to the pooled prevalence, fatigue, dyspnea, 239 and confusion or lack of concentration were the most common and prevalent long 240 COVID symptoms among African populations. Fatigue, dyspnea, and confusion or lack of concentration were all prevalent (95% CI) at 41% [26%-56%], 25% [12%-241 242 38%], and 40% [12%-68%], respectively (Figure 3). A study of 845 long COVID 243 participants found that fatigue, brain fog, loss of concentration and forgetfulness, 244 dyspnea, and joint and muscle pains were the most common symptoms in African populations (Table 1). However, due to missing data, we were unable to include this 245 246 in the meta-analysis.

Other common symptoms were arthralgia, myalgia, depression, chest pain, headache, anxiety, and cough (**Figure 3**). Even though the test of heterogeneity between studies was high ($I^2 = 97.60\%$), the test of group difference was not statistically significant (P = 0.43).

Using Egger's regression and Begg's tests, we assessed the publication bias of nine studies that included long COVID prevalence in African populations. With z = 1.49 (P = 0.1538) and z = -0.52 (P = 1.3978), the publication bias was less likely.

Study	Effect Size with 95% Cl	Weight (%)
South Africa		
Dryden et al., 2022	0.67 [0.65, 0.69]	11.36
Mendelsohn et al., 2022	0.26 [0.23, 0.30]	11.32
Heterogeneity: $\tau^2 = 0.08$, $I^2 = 99.74\%$, $H^2 = 391.44$	-0.47 [0.07, 0.86]	
Test of $\theta_1 = \theta_1$: Q(1) = 391.44, p = 0.00		
Egypt		
Aly et al., 2022	0.57 [0.48, 0.66]	10.93
Galal et al., 2021 -	0.60 [0.55, 0.65]	11.26
Heterogeneity: τ ² = 0.00, I ² = 0.05%, H ² = 1.00	0.59 [0.55, 0.64]	
Test of $\theta_1 = \theta_1$: Q(1) = 0.25, p = 0.61		
Ghana		
Crankson et al., 2022	0.02 [0.02, 0.03]	11.38
Heterogeneity: τ ² = 0.00, 1 ² = .%, H ² = .	0.02 [0.02, 0.03]	
Test of $\theta_1 = \theta_1$: Q(0) = 0.00, p = .		
Nigeria		
Ogoina et al., 2021	0.59 [0.45, 0.72]	10.41
Osikomaiya et al., 2021	0.41 [0.35, 0.47]	11.19
Heterogeneity: τ [*] = 0.01, 1 [*] = 82.52%, H [*] = 5.72	0.49 [0.31, 0.66]	
Test of $\theta_1 = \theta_1$: Q(1) = 5.72, p = 0.02		
Morocco	0.474.0.00.0.581	40.00
Utmani et al., 2022 $-$	0.47 [0.38, 0.50]	10.93
Heterogeneity: T = 0.00, T = .%, H = .	0.47 [0.38, 0.50]	
lest of $\theta_1 = \theta_1$: $Q(0) = 0.00$, p = .		
Zambia		
Zulu et al. 2022 -	0 15 [0 10 0 20]	11 23
Heterogeneity: $r^2 = 0.00 L^2 = \% H^2 = $	0.15[0.10,0.20]	11.20
Test of $\Theta_{1} = \Theta_{2} \cap O(0) = -0.00$ p =	0.10[0.10, 0.20]	
1000 m^{-1}		
Overall	0.41 [0.26, 0.56]	
Heterogeneity: $\tau^2 = 0.05$, $I^2 = 99.50\%$, $H^2 = 200.89$		
Test of $\theta_1 = \theta_1$: Q(8) = 4248.29, p = 0.00		
Tast of group differences: $O_{1}(5) = 0.80$ 14 $= = 0.00$		
rest or group dimerences: Ga(o) = 808.14, p = 0.00	2	
0 .2 .4 .6	.8	
Random-ellecis REME model		

Figure 2: Forest plot of long COVID prevalence in African countries

Effect Size Weight Study with 95% CI (%) Fatigue Dryden et al., 2022 0.50 [0.48, 0.53] 3.91 Mendelsohn et al., 2022 0.35[0.28, 0.42] 3.79 0.57 [0.48, 0.66] 3.71 Aly et al., 2022 Ogoina et al., 2021 0.16 [0.06, 0.26] 3.66 0.31 [0.23, 0.40] 3.73 Osikomalya et al., 2021 Otmani et al., 2022 0.251 0.14 0.361 3.59 Kruger et al., 2022 -0.74 [0.65, 0.82] 3.73 Heterogeneity: T² = 0.04, I² = 96.71%, H² = 30.43 0.41 [0.26, 0.56] Test of 8, = 8; O(6) = 123.26, p = 0.00 Dysphoea Dryden et al., 2022 0.23 [0.21, 0.26] 3.92 Mendelsohn et al., 2022 0.20[0.14, 0.25] 3.83 Aly et al., 2022 0.17 [0.10, 0.24] 3.80 0.101 0.02, 0.181 3.75 Opping et al., 2021 Osikomalya et al., 2021 0.23 [0.15, 0.31] 3.76 Kruger et al., 2022 0.59 [0.49, 0.68] 3.68 Heterogeneity: T² = 0.03, I² = 96.60%, H² = 29.44 0.25 [0.12, 0.38] Test of 8, = 8;: O(5) = 65.04, p = 0.00 Confusion or lack of concentration Dryden et al., 2022 0.18 [0.15, 0.20] 3.92 0.14 [0.05, 0.23] 3.70 Otmani et al., 2022 Galal et al., 2021 0.57 [0.51, 0.63] 3.83 - 0.71 [0.62, 0.80] 3.71 Kruper et al., 2022 Heterogeneity: 7² = 0.08, 1² = 98.91%, H² = 91.64 0.40 [0.12, 0.68] Test of 0, = 0;: O(3) = 262.02, p = 0.00 Other symptoms Mendelsohn et al., 2022 (Loss of taste) 0.20 [0.14, 0.26] 3.83 Aly et al., 2022(Depression) 0.48 [0.39, 0.57] 3.71 0.18 [0.07, 0.28] 3.64 Ogoina et al., 2021(Cough) Osikomaiya et al., 2021(Chest pain) 0.24 [0.16, 0.32] 3.76 Otmani et al., 2022(Anxiety) 0.21 [0.10, 0.33] 3.59 Zulu et al., 2022(Cough) 0.37 [0.19, 0.55] 3.16 Zulu et al., 2022(Headache) 0.26 [0.09, 0.42] 3.28 Zulu et al., 2022(Chest pain) 0.22[0.07, 0.38] 3.33 Galal et al., 2021(Myalgia) 0.60 [0.54, 0.66] 3.83 Galal et al., 2022(Arthralgia) 0.57 [0.51, 0.63] 3.83 Heterogeneity: 1² = 0.03, 1² = 92.84%, H² = 13.97 0.34 [0.23, 0.44] Test of 8, = 8; O(9) = 172.17, p = 0.00 Overall 0.351 0.27, 0.421 Hoterogeneity: T² = 0.04, I² = 97.60%, H² = 41.59 Test of 8, = 8;: O(26) = 972.38, p = 0.00 Test of group differences: O₄(3) = 2.79, p = 0.43 6 2 à à à. Random-effects REML model

257 Figure 3: Forest plot of predominant symptoms of long COVID in African populations

258

256

259

260 **3.3. Narrative synthesis**

261

The narrative synthesis reported all statistically significant key findings (P 0.05) and important findings related comorbidities associated with long COVID and

264 pathophysiology.

265 Long-COVID was statistically associated with advanced age and female sex in African populations (P ≤0.05).^{11,28} In terms of clinical symptoms, long COVID was 266 statistically associated with more than three long COVID symptoms in the acute 267 268 phase, including initial fatigue and dyspnea, post-recovery stress, sadness and sleep disturbances, and loss of appetite at symptoms onset (P ≤ 0.05).^{11,26,27,28} Our review 269 270 also found that long COVID was statistically associated with mild, moderate, and severe COVID-19 (P ≤0.05).^{11,23,24,28} Long COVID was also associated with 271 272 supplemental oxygen during intensive care unit (ICU) admission and pulmonary involvement in chest CT scan (P ≤0.05).^{11,20,29} Obesity, hypertension, diabetes 273 274 mellitus, and the presence of any chronic illness were all statistically significant predictors of long COVID.^{11,29,30} The most common comorbidities found in long 275 276 COVID in African populations were hypertension, obesity, hyperlipidaemia, diabetes 277 mellitus, human immunodeficiency virus (HIV), ischemic heart disease, chronic 278 obstructive pulmonary disease (COPD)/asthma, malignancies, previous tuberculosis 279 (TB), renal disease, thrombosis (previous blood clots), and psychiatric diseases, as 280 shown in **Table 1** and **Figure 4**. In terms of pathophysiology, African studies found 281 that long COVID patients had higher microclot and platelet poor plasma (PPP) viscosity when compared to control groups.^{18,21,22,25} Furthermore, high levels of six 282 283 inflammatory molecules were detected, including serum Amyloid A (SAA), -2 antiplasmin (-2AP), platelet factor 4 (PF4), Von Willebrand Factor (VWF), 284 285 endothelial-leukocyte adhesion molecule 1 (E-selectin), and platelet endothelial cell adhesion molecule-1 (PECAM-1).22 286



- 288
- 289 Figure 1: Potential long COVID risk factors in Africa
- 290
- 291

292 4. Discussion

293

We conducted a systematic review to determine the burden of long COVID, 294 prevalent symptoms, key findings, risk factors, and plausible pathophysiology in 295 296 African populations. This review included fourteen studies on long COVID conducted 297 in African populations. This study included 6,030 previously SARS-CoV-2 infected participants and 2,954 long COVID patients. Females outnumbered males among 298 long COVID patients. The ages ranged from one to 85 years. The pooled prevalence 299 (95% CI) of long COVID in the African population was 41% [26%-56%]. In 300 comparison to a review of fifty included studies, 41 of which were meta-analysed, the 301 global estimated pooled prevalence of long COVID-19 was 43% [39%-46%].¹³ Long 302 303 COVID prevalence was higher in Africa than in North America [31% (21%-43%)], but

lower in Europe [44% (32%-56%)] and Asia [51% (37%-65%)].¹³ The prevalence 304 (95%CI) of the most common symptoms were 41% [26%-56%] fatigue, 40% [12%-305 68%] confusion or lack of concentration, and 25% [12%-38%] dyspnoea. Our result 306 307 was also on same line with a global review showing that the fatigue was the most common symptom reported with a prevalence of 23% [17%-30%]^{13,31}, followed by 308 confusion or lack of concentration 14% [10%-19%]¹³ and dyspnoea 13% [11%-309 15%1¹³. Even though the African long COVID prevalence was slightly lower than the 310 global prevalence, the Africans had higher rates of fatigue, confusion or lack of 311 312 concentration, and dyspnea. Further research may be required to clarify these 313 findings.

Our findings also revealed that Long-COVID was statistically associated with 314 advanced age and being female in African populations.^{11,28} Our findings were 315 316 consistent with the findings of Chen et al., who found that female sex was a risk 317 factor for long COVID. Long COVID was statistically associated with more than three long COVID symptoms in the acute phase, including initial fatigue and dyspnea, 318 319 post-recovery stress, sadness, and sleep disturbances, and loss of appetite at the onset of symptoms.^{11,26-28} Our findings support the results from previous systematic 320 review and meta-analysis on long COVID symptoms.^{13,31,32} 321

Our study also found that long COVID was statistically associated with mild, moderate, and severe COVID-19.^{11,23,24,28} This could be explained by a significant increase in the rates of thrombotic events following even a mild COVID-19 infection.^{22,33} Long COVID was also statistically associated with supplemental oxygen during ICU admission and pulmonary involvement in chest CT scan.^{11,20,29} A study that looked at the long-term outcomes of patients who needed ICU admission for severe COVID-19 found that the long-term effects of severe COVID-19 lasted

more than six months.³⁴ Similarly, a 12-month study found that a chest CT scan in acute COVID-19 correlates with pulmonary function and respiratory symptoms after SARS-CoV-2 infection.³⁵ Obesity, hypertension, diabetes mellitus, and the presence of any chronic illness were all statistically significant predictors of long COVID.^{11,29,30} Preexisting conditions such as obesity and comorbidities were also found to be positively associated with post COVID-19 condition in multiple studies.^{36,37}

In point of view pathophysiology, African studies demonstrated high microclot and 335 336 Platelet poor plasma (PPP) viscosity were statistically higher in long COVID patients compared to the control groups.^{18,21,22,25} In addition, high levels of six inflammatory 337 molecules SAA, α-2AP, PF4, VWF, E-selectin and PECAM-1, are known to be key 338 drivers of endothelial and clotting pathology.²² In fact, long COVID was associated 339 340 with additional distinctive innate and adaptive immune traits, consisting of a weaker initial inflammatory response.³⁸ The viral tropism defined by the entry into cells 341 342 through a widely expressed Angiotensin-Converting Enzyme 2 (ACE2) receptor 343 makes it highly possible that many organs have the potential to undergo not only 344 acute but also chronic damage, adding to the very diverse clinical picture of long COVID.^{39,40} 345 Long COVID may generate further complications based on 346 hypercoagulation and thrombosis associated to advanced age and pre-existing co-347 morbidities. As an example, in African populations, a study reported that two people living with HIV (PLWH) developed cardiovascular complications (myocardial 348 infarction and arrhythmia) during the three months of follow-up.⁴¹ HIV status was 349 350 strongly associated with long COVID, raising concerns that this condition might be common among PWH recovering from COVID-19.¹² Certainly, two main hypotheses 351 352 should be considered. Firstly, it is well known how COVID-19 may cause and worsen 353 cardiovascular events, especially in patients who are at increased risk such as 354 PLWH who also is in increased risk of hypertension, diabetes mellitus, dyslipidaemia, previous thrombosis and obesity.^{42,43} Secondly, in patients with 355 356 known pre-existing cardiovascular risk factors, SAA, α -2AP, PF4, VWF, E-selectin 357 and PECAM-1 induced by the presence of SARS-CoV-2 may have worsened and accelerated the cardiac damage and caused stress cardiomyopathy.^{22,41,43,44} Turner 358 359 et al. explained long COVID as the interaction between endothelial dysfunction, 360 chronic inflammation, and platelet activation generating the formation of micro clot, 361 inducing the raised of the above mentioned six inflammatory molecules and hypercoagulation and thrombosis.²² This is significant because diabetes type 2 is a 362 363 risk factor for long COVID in African populations and is associated with hypercoagulation states.¹⁸ Comorbidities associated with an increased risk of long 364 365 COVID, and hypercoagulability include cardiovascular disease, renal failure, venous thrombosis, cancer, and COPD.⁴⁵ 366

367 Given that Africa has the lowest COVID-19 vaccination rate among continents, this 368 could be another risk factor for long COVID in Africa. A systematic review of six 369 studies (n=17,256,654 individuals) investigating the impact of vaccines before acute 370 SARS-CoV-2 infection found a low level of evidence suggesting that vaccination 371 before SARS-CoV-2 infection could reduce the risk of subsequent long-COVID infection.⁴⁶ As with most common chronic conditions, the causation is not yet well 372 373 understood. However, long COVID causation should be viewed as a multifactorial 374 interaction between the individual co-morbidities, past medical history, SARS-CoV-2 375 variants, genetic factors, and ethnicity. **Figure 4** in our study has clearly highlighted 376 the multifactorial factors of long COVID in African populations. The reason that some 377 individuals are more prone to develop long COVID possibly lies in their genetic 378 profile primarily related to the immune system, such as human leukocyte antigen

(HLA).⁵ Long COVID may be the result of tissue/organ damage, or inflammatory and
immune pathways dysfunction (including chronic inflammation, hypercoagulation,
thrombosis, hyperactive immune cells, and autoimmunity because of molecular
mimicry).^{11,18,21,22,25} This results to difference long COVID prevalence rates and
symptoms among populations.

384 To the best of our knowledge, this is the first systematic review and meta-analysis of 385 long COVID and its most common symptoms. This review will be useful in future 386 research on long COVID and comorbidities in African populations, particularly 387 comorbidities associated with thrombosis risk in African populations. The review's 388 main weaknesses were the small number of included studies, poor study design of 389 included studies, missing data, and high heterogeneity between studies. However, 390 publication bias was less likely because the Egger's regression and Begg's tests were not statistically significant with z = 1.49 (P = 0.1538) and z = -0.52 (P = 391 392 1.3978), respectively, and the test of group difference for long COVID symptoms was 393 not statistically significant (P = 0.43).

394 **5. Conclusion**

395 This review looked at the various characteristics of long COVID in Africa. Despite 396 having the lowest number of COVID-19 cases, the prevalence of long COVID cases 397 in Africa was closer to the global prevalence. Even though fatigue, dyspnea, and 398 confusion or lack of concentration were the most common symptoms globally and in 399 Africa, their prevalence rates were higher in Africa. Long COVID was associated with 400 advanced age, female sex, three long COVID symptoms in the acute phase, initial 401 fatigue and dyspnea, post-recovery stress, sadness, and sleep disturbances, and 402 loss of appetite at symptoms onset, mild, moderate, and severe, pre-existing obesity, 403 hypertension, diabetes mellitus, and the presence of any chronic illness in African

populations. According to our review, the pathophysiology of long COVID is
explained by high microclot and PPP viscosity. This may raise the risk of additional
cardiovascular complications in African populations. Future research should focus on
long COVID, and comorbidities associated with hypercoagulation and thrombosis in
African populations.

409

410 **6. Abbreviations**

411 -2AP: -2 antiplasmin; ACE2: Angiotensin-Converting Enzyme 2; AIDS: acquired 412 immune deficiency syndrome; ARDS: acute respiratory distress syndrome; BMI: 413 body mass index; CDC: Centers for Disease Control and Prevention; CCS: Chronic 414 COVID syndrome; CFS: chronic fatigue syndrome; COPD: Chronic obstructive 415 pulmonary disease; COVID-19: Coronavirus disease 2019; E-selectin: endothelial-416 leukocyte adhesion molecule 1; GORD: Gastroesophageal reflux disease; HIV: 417 human immunodeficiency virus; HLA: human leukocyte antigen; ICU: intensive care 418 unit; MIS-A: multi-system inflammatory syndrome in adults; MIS: multisystem 419 inflammatory syndrome; NICE: National Institute for Health and Care Excellence; 420 PASC: Post-Acute Sequelae of SARS-CoV-2; PECAM-1: platelet endothelial cell 421 adhesion molecule-1; PLWH: persons living with HIV; PF4: platelet factor 4; PPP: 422 platelet poor plasma; RNA: ribonucleic acid; RT-PCR: Reverse transcription 423 polymerase chain reaction; SAA: serum Amyloid A; SARS-CoV-2: Severe acute 424 respiratory syndrome coronavirus 2; TB: tuberculosis; UN: United Nations; VWF: 425 Von Willebrand Factor; WHO: World Health Organization

426 **6. Footnotes**

Author Contributions: PSN conceived the review. PSN and JLT searched potential
 peer review manuscripts. PSN and JLT conducted the data extraction. JLT

undertook the data analysis. PSN and JLT drafted the manuscript. PSN, JLT and

430	RTE edited the manuscript. This version was reviewed and approved by all the
431	authors.
432	Informed Consent Statement: Not applicable
433	Availability of data and materials: All Data and material are available in this
434	manuscript.
435	Competing interests: The authors declare that they have no financial or personal
436	relationships that may have inappropriately influenced them in writing this article.
437	Funding Source: None
438	Ethical Approval statement: Not applicable
439	
440	7. References
441	
442	1. Aly MAEG, Saber HG. Long COVID and chronic fatigue syndrome: A survey
443	of elderly female survivors in Egypt. International journal of clinical practice
444	2021;75(12): e14886.
445	2. Davis HE, Assaf GS, McCorkell L, Wei H, Low RJ, Re'em Y, et al.
446	Characterizing long COVID in an international cohort: 7 months of symptoms
447	and their impact. EClinicalMedicine 2021; 38:101019.
448	3. Sudre Carole H, Murray Benjamin, Varsavsky Thomas, Graham Mark S,
449	Penfold Rose S, Bowyer Ruth C, et al. Attributes and predictors of long
450	COVID. 2021;27(4):626-31.
451	4. CDC. Long COVID or Post-COVID Conditions. In:
452	https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/index.html.
453	<u>2022</u> .

454 5. Akbarialiabad H, Taghrir MH, Abdollahi A, Ghahramani N, Kumar M, Paydar 455 S, et al. Long COVID, a comprehensive systematic scoping review. Infection 456 2021;49(6):1163-86. 457 6. Greenhalgh T, Knight M, A'Court C, Buxton M, Husain L. Management of post-acute covid-19 in primary care. BMJ (Clinical research ed.) 458 459 2020;370:m3026. 7. Baig AM. Deleterious Outcomes in Long-Hauler COVID-19: The Effects of 460 461 SARS-CoV-2 on the CNS in Chronic COVID Syndrome. ACS chemical neuroscience 2020;11(24):4017-20. 462 463 8. WHO. COVID-19 Weekly Epidemiological Update, Edition 123 published 21 464 December 2022. https://www.who.int/publications/m/item/covid-19-weeklyepidemiological-update---21-december-2022 465 466 9. United Nations Population Division. World Population Prospects. In: https://population.un.org/wpp/. 2019. 467 468 10. Wamai RG, Hirsch JL, Van Damme W, Alnwick D, Bailey RC, Hodgins S, et 469 al. What Could Explain the Lower COVID-19 Burden in Africa despite 470 Considerable Circulation of the SARS-CoV-2 Virus? International journal of environmental research and public health 2021;18(16). 471 11. Dryden M, Mudara C, Vika C, Blumberg L, Mayet N, Cohen C, et al. post-472 COVID-19 condition 3 months after hospitalisation with SARS-CoV-2 in South 473 474 Africa: a prospective cohort study. The Lancet. Global health 2022;10(9): e1247-56. 475 12. Peluso MJ, Spinelli MA, Deveau TM, Forman CA, Munter SE, Mathur S, et al. 476 Post acute sequelae and adaptive immune responses in people with HIV 477

478	recovering from SARS-COV-2 infection. AIDS (London, England)
479	2022;36(12):F7-F16.
480	13. Chen C, Haupert SR, Zimmermann L, Shi X, Fritsche LG, Mukherjee B.
481	Global Prevalence of Post-Coronavirus Disease 2019 (COVID-19) Condition
482	or Long COVID: A Meta-Analysis and Systematic Review. J Infect Dis. 2022
483	;226(9):1593-1607.
484	14. Rinaldi R, Basile M, Salzillo C, Grieco DL, Caffè A, Masciocchi C, Lilli L,
485	Damiani A, La Vecchia G, Iannaccone G, Bonanni A, De Pascale G, Murri R,
486	Fantoni M, Liuzzo G, Sanna T, Massetti M, Gasbarrini A, Valentini V, Antonelli
487	M, Crea F, Montone RA, On Behalf Of The Gemelli Against Covid Group.
488	Myocardial Injury Portends a Higher Risk of Mortality and Long-Term
489	Cardiovascular Sequelae after Hospital Discharge in COVID-19 Survivors. J
490	Clin Med. 2022;11(19):5964.
491	15. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD,
492	Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw
493	JM, Hróbjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S,
494	McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P,
495	Moher D. The PRISMA 2020 statement: an updated guideline for reporting
496	systematic reviews. Syst Rev. 2021;10(1):89.
497	16.Lo CK, Mertz D, Loeb M. Newcastle-Ottawa Scale: comparing reviewers to
498	authors' assessments. BMC Med Res Methodol. 2014 Apr 1; 14:45. doi:
499	10.1186/1471-2288-14-45. PMID: 24690082; PMCID: PMC4021422.
500	17. Higgins JPT, Green S. eds. Cochrane Handbook for Systematic Reviews of
501	Interventions 4.2.6 [updated September 2006]. In: Chichester, UK: John Wiley
502	& Sons, Ltd, 2006:6. The Cochrane Library

503	18. Pretorius E, Vlok M, Venter C, Bezuidenhout JA, Laubscher GJ, Steenkamp
504	J, Kell DB. Persistent clotting protein pathology in Long COVID/Post-Acute
505	Sequelae of COVID-19 (PASC) is accompanied by increased levels of
506	antiplasmin. Cardiovasc Diabetol. 2021;20(1):172.
507	19.Kruger A, Vlok M, Turner S, Venter C, Laubscher GJ, Kell DB, Pretorius E.
508	Proteomics of fibrin amyloid microclots in long COVID/post-acute sequelae of
509	COVID-19 (PASC) shows many entrapped pro-inflammatory molecules that
510	may also contribute to a failed fibrinolytic system. Cardiovasc Diabetol.
511	2022;21(1):190.
512	20. El Otmani H, Nabili S, Berrada M, Bellakhdar S, El Moutawakil B, Abdoh Rafai
513	M. Prevalence, characteristics, and risk factors in a Moroccan cohort of Long-
514	Covid-19. Neurol Sci. 2022;43(9):5175-5180.
515	21. Walker M, Federico EM, Kell DB, Dupont C, Proal A, Pretorius E. Detection
516	and Characterization of Fibrin/Amyloid Microclots in Patients with Post-Acute
517	Sequelae of Covid-19. Circulation. 2022 Nov 8;146(Suppl_1): A15637
518	22. Turner S, Naidoo C, Usher T, Kruger A, Venter C, Laubscher GJ, Khan MA,
519	Kell DB, Pretorius E. Increased levels of inflammatory molecules in blood of
520	Long COVID patients point to thrombotic endotheliitis. medRxiv. 2022 Jan 1.
521	https://www.medrxiv.org/content/10.1101/2022.10.13.22281055v1
522	23. Ogoina D, James HI, Ogoinja SZ. Post-Discharge Symptoms among
523	Hospitalized COVID-19 Patients in Nigeria: A Single-Center Study. Am J Trop
524	Med Hyg. 2021;105(3):731-736.
525	24. Osikomaiya B, Erinoso O, Wright KO, Odusola AO, Thomas B, Adeyemi O,
526	Bowale A, Adejumo O, Falana A, Abdus-Salam I, Ogboye O, Osibogun A,

527	Abayomi A. 'Long COVID': persistent COVID-19 symptoms in survivors
528	managed in Lagos State, Nigeria. BMC Infect Dis. 2021;21(1):304.
529	25. Pretorius E, Venter C, Laubscher GJ, Kotze MJ, Oladejo SO, Watson LR,
530	Rajaratnam K, Watson BW, Kell DB. Prevalence of symptoms, comorbidities,
531	fibrin amyloid microclots and platelet pathology in individuals with Long
532	COVID/Post-Acute Sequelae of COVID-19 (PASC). Cardiovasc Diabetol.
533	2022;21(1):148.
534	26. Zulu JE, Banda D, Hines JZ, Luchembe M, Sivile S, Siwingwa M, Kampamba
535	D, Zyambo KD, Chirwa R, Chirwa L, Malambo W, Barradas D, Sinyange N,
536	Agolory S, Mulenga LB, Fwoloshi S. Two-month follow-up of persons with
537	SARS-CoV-2 infection-Zambia, September 2020: a cohort study. Pan Afr Med
538	J. 2022; 41:26.
539	27. Aly MAEG, Saber HG. Long COVID and chronic fatigue syndrome: A survey
540	of elderly female survivors in Egypt. Int J Clin Pract. 2021 Dec;75(12):
541	e14886.
542	28. Mendelsohn AS, Nath N, De Sá A, Von Pressentin KB. Two months follow-up
543	of patients with non-critical COVID-19 in Cape Town, South Africa. S Afr Fam
544	Pract (2004). 2022 Feb 10;64(1): e1-e6.
545	29. Galal I, Hussein AA, Amin MT, Saad MM, Zayan HE, Abdelsayed MZ,
546	Moustafa MM, Ezzat AR, Helmy RE, Abd_Elaal HK, Al Massry NA.
547	Determinants of persistent post-COVID-19 symptoms: value of a novel
548	COVID-19 symptom score. The Egyptian Journal of Bronchology.
549	2021;15(1):1-8.

550	30. Crankson S, Pokhrel S, Anokye NK. Determinants of COVID-19-Related
551	Length of Hospital Stays and Long COVID in Ghana: A Cross-Sectional
552	Analysis. Int J Environ Res Public Health. 2022;19(1):527.
553	31. Global Burden of Disease Long COVID Collaborators, Wulf Hanson S,
554	Abbafati C, Aerts JG, Al-Aly Z, Ashbaugh C, Ballouz T, Blyuss O, Bobkova P,
555	Bonsel G, Borzakova S, Buonsenso D, Butnaru D, Carter A, Chu H, De Rose
556	C, Diab MM, Ekbom E, El Tantawi M, Fomin V, Frithiof R, Gamirova A,
557	Glybochko PV, Haagsma JA, Haghjooy Javanmard S, Hamilton EB, Harris G,
558	Heijenbrok-Kal MH, Helbok R, Hellemons ME, Hillus D, Huijts SM, Hultström
559	M, Jassat W, Kurth F, Larsson IM, Lipcsey M, Liu C, Loflin CD, Malinovschi A,
560	Mao W, Mazankova L, McCulloch D, Menges D, Mohammadifard N, Munblit
561	D, Nekliudov NA, Ogbuoji O, Osmanov IM, Peñalvo JL, Petersen MS, Puhan
562	MA, Rahman M, Rass V, Reinig N, Ribbers GM, Ricchiuto A, Rubertsson S,
563	Samitova E, Sarrafzadegan N, Shikhaleva A, Simpson KE, Sinatti D, Soriano
564	JB, Spiridonova E, Steinbeis F, Svistunov AA, Valentini P, van de Water BJ,
565	van den Berg-Emons R, Wallin E, Witzenrath M, Wu Y, Xu H, Zoller T, Adolph
566	C, Albright J, Amlag JO, Aravkin AY, Bang-Jensen BL, Bisignano C,
567	Castellano R, Castro E, Chakrabarti S, Collins JK, Dai X, Daoud F, Dapper C,
568	Deen A, Duncan BB, Erickson M, Ewald SB, Ferrari AJ, Flaxman AD, Fullman
569	N, Gamkrelidze A, Giles JR, Guo G, Hay SI, He J, Helak M, Hulland EN,
570	Kereselidze M, Krohn KJ, Lazzar-Atwood A, Lindstrom A, Lozano R, Malta
571	DC, Månsson J, Mantilla Herrera AM, Mokdad AH, Monasta L, Nomura S,
572	Pasovic M, Pigott DM, Reiner RC Jr, Reinke G, Ribeiro ALP, Santomauro DF,
573	Sholokhov A, Spurlock EE, Walcott R, Walker A, Wiysonge CS, Zheng P,
574	Bettger JP, Murray CJL, Vos T. Estimated Global Proportions of Individuals

575	With Persistent Fatigue, Cognitive, and Respiratory Symptom Clusters
576	Following Symptomatic COVID-19 in 2020 and 2021. JAMA.
577	2022;328(16):1604-1615.
578	32. Aiyegbusi OL, Hughes SE, Turner G, Rivera SC, McMullan C, Chandan JS,
579	Haroon S, Price G, Davies EH, Nirantharakumar K, Sapey E, Calvert MJ; TLC
580	Study Group. Symptoms, complications and management of long COVID: a
581	review. J R Soc Med. 2021;114(9):428-442.
582	33. Al-Aly Z, Bowe B, Xie Y. Long COVID after breakthrough SARS-CoV-2
583	infection. Nat Med. 2022;28(7):1461-1467.
584	34. Neville TH, Hays RD, Tseng CH, Gonzalez CA, Chen L, Hong A, Yamamoto
585	M, Santoso L, Kung A, Schwab K, Chang SY, Qadir N, Wang T, Wenger NS.
586	Survival After Severe COVID-19: Long-Term Outcomes of Patients Admitted
587	to an Intensive Care Unit. J Intensive Care Med. 2022;37(8):1019-1028.
588	35. Steinbeis F, Thibeault C, Doellinger F, Ring RM, Mittermaier M, Ruwwe-
589	Glösenkamp C, Alius F, Knape P, Meyer HJ, Lippert LJ, Helbig ET, Grund D,
590	Temmesfeld-Wollbrück B, Suttorp N, Sander LE, Kurth F, Penzkofer T,
591	Witzenrath M, Zoller T. Severity of respiratory failure and computed chest
592	tomography in acute COVID-19 correlates with pulmonary function and
593	respiratory symptoms after infection with SARS-CoV-2: An observational
594	longitudinal study over 12 months. Respir Med. 2022; 191:106709.
595	36. Xie Y, Al-Aly Z. Risks and burdens of incident diabetes in long COVID: a
596	cohort study. Lancet Diabetes Endocrinol. 2022;10(5):311-321.
597	37. Xie Y, Xu E, Bowe B, Al-Aly Z. Long-term cardiovascular outcomes of COVID-
598	19. Nat Med. 2022;28(3):583-590.

599	38. García-Abellán J, Padilla S, Fernández-González M, García JA, Agulló V,
600	Andreo M, Ruiz S, Galiana A, Gutiérrez F, Masiá M. Antibody Response to
601	SARS-CoV-2 is Associated with Long-term Clinical Outcome in Patients with
602	COVID-19: a Longitudinal Study. J Clin Immunol. 2021;41(7):1490-1501.
603	39. Gavriatopoulou M, Korompoki E, Fotiou D, Ntanasis-Stathopoulos I,
604	Psaltopoulou T, Kastritis E, et al. Organ-specific manifestations of COVID-19
605	infection. Clinical and experimental medicine 2020;20(4):493-506.
606	40. Augustin M, Schommers P, Stecher M, Dewald F, Gieselmann L, Gruell H, et
607	al. post-COVID syndrome in non-hospitalised patients with COVID-19: a
608	longitudinal prospective cohort study. The Lancet regional health. Europe
609	2021; 6:100122.
610	41.Mazzitelli M. Trunfio M. Sasset L. Leoni D. Castelli E. Lo Menzo S. et al.
611	Factors Associated with Severe COVID-19 and Post-Acute COVID-19
612	Syndrome in a Cohort of People Living with HIV on Antiretroviral Treatment
613	and with Undetectable HIV RNA. Viruses 2022;14(3).
	40 Niching M. Margo DW. Han X. Lawis DD. Wei JO. COVID 40 and
614	42. Nishiga M, Wang DW, Han Y, Lewis DB, Wu JC. COVID-19 and
615	cardiovascular disease: from basic mechanisms to clinical perspectives.
616	Nature reviews. Cardiology 2020;17(9):543-58.
617	43. Jabri A, Kalra A, Kumar A, Alameh A, Adroja S, Bashir H, et al. Incidence of
618	Stress Cardiomyopathy During the Coronavirus Disease 2019 Pandemic.
619	JAMA network open 2020;3(7): e2014780.
620	44. Rajpal S, Tong MS, Borchers J, Zareba KM, Obarski TP, Simonetti OP, et al.
621	Cardiovascular Magnetic Resonance Findings in Competitive Athletes
622	Recovering From COVID-19 Infection. JAMA cardiology 2021;6(1):116-8.

- 45. Rahaghi FN, Pistenmaa CL. Hypercoagulation in COPD: the clot thickens.
- 624 ERJ Open Res. 2021;7(4):00534-2021.
- 46. Notarte KI, Catahay JA, Velasco JV, Pastrana A, Ver AT, Pangilinan FC, et al.
- Impact of COVID-19 vaccination on the risk of developing long-COVID and on
- existing long-COVID symptoms: A systematic review. EClinicalMedicine 2022;
- 628
 53:101624.

Table 1 summarises the evidence-based studies of long COVID-19 in Africa

Study ID/Settings	Study population	Study designs	Long COVID	Predominant	Comorbidities	Key findings
			prevalence	symptoms		
Dryden et al., 2022/South Africa	1,873 enrolled hospitalized COVID-19 participants were followed up three months after hospital discharge. 960 (53·1%) were women and 913 (48·8%) were men, the median age was 52 years (41–62)	A prospective, observational cohort study	1,249/1873(66.7%)	Fatigue (50.3%), shortness of breath (23.4%), confusion or lack of concentration (17.5%), headaches (13.8%), and problems seeing/blurred vision (10.1%).	The most common self-reported comorbidities were hypertension (n=669; 35.7%), obesity (n=474; 25.3%), and diabetes mellitus (n=418; 22.3%). HIV was reported by 95 (5.1%) participants.	age ≥65 years (aOR) 1.62; 95%Cl 1.00- 2.61]; female sex (aOR 2.00; 95% Cl 1.51-2.65); requiring supplemental oxygen during admission (aOR 1.44; 95% Cl 1.06- 1.97); ICU admission (aOR 1.87; 95% Cl 1.36-2.57); pre- existing obesity (aOR 1.44; 95% Cl 1.09- 1.91); and the presence of ≥4 acute symptoms (aOR 1.94; 95% Cl 1.19- 3.15)
Mendelsohn et al., 2022/South Africa	174 long COVID among 653 COVID-19 infected patients. The mean age of participants was 50.3 (13.6) years; 62% were female.	Retrospective cross- sectional study	172/653 (35%)	Fatigue 60 (34.5%) Dyspnoea 35 (20.1%) Loss of taste 34 (19.5%) Loss of smell 32 (18.4%) Headache 27 (15.5%) Body aches 26 (14.9%) Chest pain 19 (10.9%) Gastrointestinal complaints 21 (12.1%) Palpitations 18 (10.3%) Rash 11 (6.3%)	Diabetes 35 (22.0%); Hypertension 77 (48.4%) ischemic heart disease 7 (4.4%) COPD/asthma 10 (6.3%) Prior TB 1 (0.6%) HIV 1 0.6 Other 7 (4.4%)	Sex, age, baseline severity of disease, or number of initial COVID-19 symptoms were predictive of self- reported dyspnoea, fatigue, ≥ 3 long COVID symptoms, or self-reported non- recovery.
Aly et al., 2021/Egypt	A total of 115 females	A retrospective cross-	66/115 (57%)	Dyspnoea 20 (17.4)		The presence of
	among them 66 had	sectional study		Cough 10 (8.7)		post-recovery
	long COVID. The mean			Chest pain 9 (7.8)		symptoms was
	age was 73.18 ± 6.42.			Palpitations 13		significantly related

				(11.3) Insomnia 28 (24.3) Headache 14 (12.2) Loss of smell and taste 14 (12.2) Stress 65 (56.5) Sadness 55 (47.8) Fatigue 66 (57.4) Cognitive dysfunction 29 (25.2) Recurrent falls 29 (25.2) Incontinence 21 (18 3)		to stress (P = .005), sadness (P = .007) and sleep disturbances (P < .001)
Crankson et al., 2022/Ghana	2334 patients, among them 50 had long COVID. 60.1% were men and 39.9% were women. The majority were aged from 30 to 59 years (57.5%)	A Cross-Sectional Analysis	50/2334 (2%)	N/A	N/A	COVID-19 patients with hypertension and diabetes mellitus spent almost 2 days longer in hospital (p = 0.00 , 95% CI = 1.42-2.33) and had 4 times the odds of long COVID (95% CI = $1.61-10.85$, p = 0.003) compared to those with no comorbidities.
Ogoina et al., 2021/Nigeria	51 previously hospitalized COVID-19 patients (median age, 46 years; male, 66.7%) were studied.	Retrospective review	9/51 (17.65%)	Cough: 9 Fatigue: 8 Short of breath: 5 Chest pain: 4 Palpitations: 2 Anxiety: 3 Anorexia: 3	History of diabetes, n (%): 4 History of hypertension, n (%): 8	Mild COVID-19 (P = 0.029)
Osikomaiya et al., 2021/Nigeria	274 patients were enrolled in the study. A majority were within the age group > 35 to ≤ 49 years (38.3%), and male (66.1%).	A retrospective study design	112/274 (40.9%)	Easy fatigability 35 (12.8) Myalgia 24 (8.8) Cough 25 (9.2) Dyspnea 26 (9.5) Chest pain 27 (9.8) Loss of appetite 24 (8.8) Palpitations 20 (7.4) Headache 35 (12.8)	comorbidities (n = 52), the most common comorbidities were hypertension (72.9%) and diabetes (15.3%)	Moderate COVID-19 (aOR): 2.03 (1.19, 3.47)

				$l_{\text{nonmale}} 27 (0.9)$		
Pretorius et al., 2021/ South Africa	Blood was collected from healthy volunteers (N=13; 6 males, 7 females; mean age: 52.4±4.8) to serve as controls.	Case control study	N/A	N/A	Type 2 diabetes mellitus	A significant difference was noted between Platelet poor plasma (PPP) viscosity of controls and acute COVID-19 (p=0.001) and acute COVID-19 and Long COVID/PASC (p=0.002).
Kruger 2022/South Africa	99 long COVID patients and 29 healthy controls. Median age of 51 [40–60] median age	Case control study	N/A	Constant fatigue: 74% Cognitive impairment ("brain fog" / forgetfulness / poor concentration): 71%; Dyspnoea 59% Arthralgia / myalgia: 49%; Sleep disturbance: 34% Depression / anxiety: 30% Heart rate dysfunction / palpitations: 30% Recurring chest pain: 29%; Anosmia (loss of smell) 25%; Dysgeusia: (loss of taste) 25%; Low oxygen levels 13%	Hypertension 24% Hyperlipidaemia 19% Type 2 diabetes mellitus 6%	N/A
Otmani et al., 2022/Marocco	118 healthcare workers who endured the Covid-19 infection and 118 matched controls. 71% were females. Average age-median (years) 29 (21–54)	case-control study	56/118 (47.4%)	At least one symptom 56(47.4%) Myalgia 13.3% Anxiety 21.7% Attention disorders, memory impairment "brain fog" 14.4% Sleep disorders 12% Palpitations 10.8% Arthralgia 9.6% Asthenia 25.3% Chest pain 8.4%	N/A	Pulmonary involvement in chest CT scan

				Anosmia/hyposmia 9.6%		
Zulu et al., 2022/Zambia	27 participants. Mean participant age was 32 years (range: 1-85 years). 17 (63.0%) were females	Prospective cohort study	27/182 (37%)	Cough 10 (37.0) Rhinorrhea 5 (18.5) Headache 7 (25.9) Chest pain 6 (22.2) Arthralgia 4 (14.8)	HIV 2(7.4%)	Those with five or more symptoms at onset had nearly (p=0.03) Participants with loss of appetite at symptoms onset (p=0.01).
Galal et al., 2021/Egypt	430 participants. They were 156 males and 274 females, their mean age was 37.4 ± 12.6 years, and the range was 12–74 years.	Cross-sectional study	268/430 (60%)	myalgia (60.0%), arthralgia (57.2%), restriction of daily activities (57.0%), and sleeping troubles (50.9%), followed by anorexia (42.6%), chest pain (32.6%), gastritis (32.3%), cough (29.3%), and dyspnea (29.1%).	Diabetes mellitus: 10.9% Hypertension: 15.10% Cardiac disease: 1.9% Chronic pulmonary disease: 5.3% Renal disease: 2.3% Psychiatric disease: 1.6%	Need of oxygen therapy (< 0.001) Hypertension (0.039) Any chronic illness (0.004)
Pretorius et al., 2022/ South Africa	845 participants The gender balance (70% female) and the most reported Long COVID/PASC symptoms. The majority (i.e., 76%) of the participants were between the ages of 31–40, 41–50, and 51– 60 years.	Retrospective cohort	N/A	Fatigue, brain fog, loss of concentration and forgetfulness, shortness of breath, as well as joint and muscle pains	Hypertension, high cholesterol levels (dyslipidaemia), cardiovascular disease and type 2 diabetes mellitus (T2DM)	Microclot and platelet pathologies were associated with Long COVID/PASC symptoms that persisted after the recovery from acute COVID-19.
Walker et al., 2022/South Africa	30 matched healthy subjects and 30 PASC subjects.	Case control study	N/A	N/A	N/A	Significant microclot load was observed in the PPP of participants with PASC
Turner et al., 2022/South Africa	25 Long COVID patients. 52 (±14) years. Females were predominant.	Case control study	N/A	N/A	Hypertension: 36% Hyperlipidaemia: 40% Type 2 Diabetes Mellitus: 12%	Presence of microclotting, together with relatively high levels of six inflammatory

		Cardiovascular disease: 8% Thrombosis (previous blood clots): 8%	molecules known to be key drivers of endothelial and clotting pathology
		Cancer: 12%	

Supplementary material 1: Quality assessment of included studies

Table 2. Quality assessment of included studies.						
		Quality assessment criteria				
Author (year)	Study design	Selection	Comparability	Outcome/	Overall	
				exposure	quality	
Dryden et al., 2022	Prospective cohort study	****	**	**	8	
Mendelsohn et al.,	Retrospective cross-sectional	***	*	***	7	
2022	study					
Aly et al., 2021	Retrospective cross-sectional	**	*	**	5	
	study					
Crankson et al., 2022	Cross-Sectional Analysis	**	*	**	5	
Ogoina et al., 2021	Retrospective review	***	*	**	6	
Osikomaiya et al., 2021	Retrospective study design	**	*	**	5	
Pretorius et al., 2021	Case control study	**	*	**	5	
Kruger 2022	Case control study	***	*	***	7	
El Otmani et al., 2022	Case control study	***	**	*	6	
Zulu et al., 2022	Prospective cohort study	***	*	***	7	
Galal et al., 2021	Cross-sectional study	**	*	**	5	
Pretorius et al., 2022	Retrospective cohort	***	*	***	6	

Walker et al., 2022	Case control study	**	**	**	6
Turner et al., 2022	Case control study	**	*	***	6

Newcastle-Ottawa Scale was obtained to assess the selection, comparability and exposure of the case-control study, while the selection, comparability and outcome for the cohort study. -: no point; *: one point; **: two points; ***: three points; ***: four points.



Figure 1: Flow chart of studies reviewing long COVID in African populations

Study	Effect Size Weight with 95% CI (%)
South Africa	
Dryden et al., 2022	0.67 [0.65, 0.69] 11.36
Mendelsohn et al., 2022	0.26 [0.23, 0.30] 11.32
Heterogeneity: τ ² = 0.08, 1 ² = 99.74%, H ² = 391.44	
Test of $\theta_i = \theta_i$: Q(1) = 391.44, p = 0.00	
Egypt	
Aly et al., 2022	 0.57 [0.48, 0.66] 10.93
Galal et al., 2021	0.60 [0.55, 0.65] 11.26
Heterogeneity: τ ² = 0.00, 1 ² = 0.05%, H ² = 1.00	0.59 [0.55, 0.64]
Test of $\theta_1 = \theta_1$: Q(1) = 0.25, p = 0.61	
Ghana	
Crankson et al., 2022	0.02 [0.02, 0.03] 11.38
Heterogeneity: T [*] = 0.00, I [*] = .%, H [*] = .	0.02 [0.02, 0.03]
Test of $\theta_1 = \theta_1$: $\Omega(0) = 0.00$, $p = .$	
Nigeria	
Ogoina et al., 2021	0.59 [0.45, 0.72] 10.41
Osikomaiya et al., 2021 -	0.41 [0.35, 0.47] 11.19
Heterogeneity: 1 ⁻ = 0.01, 1 ⁻ = 82.52%, H ⁻ = 5.72	- 0.49 [0.31, 0.66]
Test of $\theta_1 = \theta_1$: Q(1) = 5.72, p = 0.02	
Morocco	
Otmani et al., 2022	0.47 [0.38, 0.56] 10.93
Heterogeneity: T = 0.00, T = .%, H = .	0.47 [0.38, 0.55]
Test of $\theta_1 = \theta_1$: $\Omega(0) = 0.00$, $p = .$	
Zambia	
Zulu et al., 2022	0.15[0.10, 0.20] 11.23
Heterogeneity: T = 0.00, T = .%, H = .	0.15 [0.10, 0.20]
Test of $\theta_1 = \theta_1$: $\Omega(0) = -0.00$, p = .	
Overall 🔷	0.41 [0.26, 0.56]
Heterogeneity: τ ² = 0.05, I ² = 99.50%, H ² = 200.89	
Test of $\theta_i = \theta_i$: Q(8) = 4248.29, p = 0.00	
Test of group differences: Q ₁ (5) = 868.14, p = 0.00	
0 .2 .4 .6	.8
Random-enects REML Model	

Figure 2: Forest plot of long COVID prevalence in African countries



Figure 1: Potential long COVID risk factors in Africa

Sludy	Effect Size with 95% CI	Weight (%)
Fatigue	- 1. A. M. M. M.	
Dryden et al., 2022	0.50 [0.48, 0.53]	3.91
Mendelsohn et al., 2022 -	0.35[0.28, 0.42]	3.79
Aly et al., 2022	0.57 [0.48, 0.66]	3.71
Ogoina et al., 2021	0.16 [0.06, 0.26]	3.66
Osikomalya et al., 2021 -	0.31 [0.23, 0.40]	3.73
Otmani et al., 2022	0.25[0.14, 0.35]	3.59
Kruger et al., 2022 -	-0.74 [0.65, 0.82]	3.73
Heterogeneity: 1 ² = 0.04, 1 ² = 96.71%, H ² = 30.43	0.41 [0.26, 0.56]	
Test of 0, = 0; O(6) = 123.26, p = 0.00		
Dyspnoea		
Dryden et al., 2022	0.23 [0.21, 0.26]	3.92
Mendelsohn et al., 2022 -	0.20[0.14, 0.26]	3.83
Aly et al., 2022	0.17 [0.10, 0.24]	3.80
Ogoina et al., 2021 -	0.10 [0.02, 0.18]	3.75
Osikomalya et al., 2021	0.23 [0.15, 0.31]	3.76
Kruger et al., 2022	0.59 [0.49, 0.68]	3.68
Heterogeneity: r ⁺ = 0.03, 1 ⁺ = 96.60%, H ⁺ = 29.44	0.25[0.12, 0.38]	
Test of $\theta_i = \theta_i$: $O(5) = 65.04$, $p = 0.00$		
Confusion or lack of concentration		
Dryden et al., 2022	0.18 [0.15, 0.20]	3.92
Otmani et al., 2022	0.14 [0.05, 0.23]	3.70
Galal et al., 2021 -	0.57 [0.51, 0.63]	3.83
Kruger et al., 2022	- 0.71 [0.62, 0.80]	3.71
Heterogeneity: T = 0.08, I = 98.91%, H = 91.64	0.40 [0.12, 0.68]	
Test of $\theta_i = \theta_i$: $O(3) = 262.02$, $p = 0.00$		
Other symptoms		
Mendelsohn et al., 2022 (Loss of taste)	0.20 [0.14, 0.26]	3.83
Aly et al., 2022(Depression)	0.48 [0.39, 0.57]	3.71
Ogoina et al., 2021(Cough)	0.18 [0.07, 0.28]	3.64
Osikomaiya et al., 2021(Chest pain)	0.24 [0.16, 0.32]	3.76
Otmani et al., 2022(Anxiety)	0.21 [0.10, 0.33]	3.59
Zulu et al., 2022(Cough)	0.37 [0.19, 0.55]	3.16
Zulu et al., 2022(Headache)	0.26 [0.09, 0.42]	3.28
Zulu et al., 2022(Chest pain)	0.22 [0.07, 0.38]	3.33
Galal et al., 2021(Myalgia)	0.60 [0.54, 0.66]	3.83
Galal et al., 2022(Arthraigia)	0.57 [0.51, 0.63]	3.83
Heterogeneity: 1" = 0.03, 1" = 92.84%, H" = 13.97	0.34 [0.23, 0.44]	
Test of $\theta_i = \theta_j$: $O(\theta) = 172.17$, $p = 0.00$		
Overall 🔶	0.35 [0.27, 0.42]	
Heterogeneity: r ⁺ = 0.04, l ⁺ = 97.60%, H ⁺ = 41.59		
Test of 8, = 8; O(26) = 972.38, p = 0.00		
Test of group differences: Q ₁ (3) = 2.79, p = 0.43	-	
0 .2 .4 .6	.8	
Random-effects REML model		

Figure 3: Forest plot of predominant symptoms of long COVID in African populations